Chemo, Targeted Therapy, Immunotherapy
Educational orientation
Expanded educational edition: 2026-09-10. This page explains therapy classes; it does not compare options for a person.
By the End of This Chapter
Compare mechanisms and explain why selectivity does not eliminate toxicity.
Learning matrix and gaps in the short edition
Core Idea
Systemic therapies move through the body. Chemotherapy usually targets fast-dividing cells or cell-division machinery. Targeted therapy aims at specific molecular dependencies. Immunotherapy attempts to help immune mechanisms recognize or attack cancer. Hormone therapy affects hormone-driven cancers. Cellular therapies modify or use living immune cells.
These categories overlap in practice, and each contains many different drugs with different indications and toxicities.
Step-by-Step Explanation
1. Circulation does not mean equal exposure
Systemic medicines can reach different regions of the body, but concentration, tissue penetration, metabolism, and elimination vary. Chemotherapies use diverse mechanisms, often affecting processes important for proliferation. Targeted therapies interfere with specific molecular features. Immunotherapies modify immune responses. These categories organize mechanisms rather than ranking treatments by quality.
2. Selectivity does not eliminate adverse effects
A target may also exist in normal cells, and the immune system can affect healthy tissues. A selective mechanism therefore does not mean a tumor-exclusive effect. Response depends on disease, target, exposure, and resistance mechanisms. Explaining why an approach might work is a mechanistic hypothesis; demonstrating benefit and harm requires evidence in the use context.
3. Biological dependence is more than target presence
Detecting a protein does not show that the tumor depends on it for survival. Even when dependence exists, blocking one step may leave other pathways sustaining the cell population. It also matters whether a substance reaches the site at sufficient and tolerable exposure. These questions connect molecular biology, pharmacology, and clinical studies without conflating their evidence levels. One experiment may demonstrate target binding; another a change in cellular function; a human study addresses additional questions. Combining these results requires preserving model, context, and endpoint instead of calling all of them “it works.”
Supporting reading: NCI: Targeted Therapy to Treat Cancer.
The Concept Illustrated
Worked Example
A cultured cell reduces proliferation after exposure to molecule X. This is a preclinical result under the experiment's conditions. It does not establish adequate distribution in the body, tolerability, or benefit in people. The correct interpretation preserves model, concentration, and experimental endpoint without promoting the finding to a validated treatment.
Essential Vocabulary
- Cytotoxic: directly damaging or killing cells.
- Targeted therapy: designed around a molecular target.
- Checkpoint inhibitor: immunotherapy affecting immune brakes.
- Endocrine therapy: hormone-pathway therapy.
What This Does Not Mean
"Targeted" does not mean harmless, and "immunotherapy" does not mean universally effective.
Builder/Data Lens
Drug names, combinations, indication, biomarker context, and line of therapy matter more than broad class labels.
Check Your Understanding
Does more specific necessarily mean safer or more effective?
Answer and reasoning
No. Specificity is a mechanistic property. Safety and efficacy depend on exposure, biology, and clinical comparisons; they cannot be deduced from a class name.
Optional Deeper Exploration
For any product, separate approval for the indication and jurisdiction, guideline use, clinical study, translational research, and preclinical research. A class containing approved medicines may also contain experimental candidates.
Go Deeper
References
- National Cancer Institute. Chemotherapy to Treat Cancer
- National Cancer Institute. Targeted Therapy for Cancer
- National Cancer Institute. Immunotherapy for Cancer